首页> 外文期刊>Drugs of today: Medicamentos de actualidad >Velaglucerase alfa: a new option for Gaucher disease treatment.
【24h】

Velaglucerase alfa: a new option for Gaucher disease treatment.

机译:Velaglucerase alfa:一种用于治疗高雪氏病的新方法。

获取原文
获取原文并翻译 | 示例
           

摘要

Type 1 Gaucher disease (GD) results from inherited beta-glucocerebrosidase gene mutations, leading to anemia, thrombocytopenia, splenomegaly, hepatomegaly and skeletal disease. Velaglucerase alfa is a beta-glucocerebrosidase produced by gene activation in a human cell line, and indicated for type 1 GD. A phase I/II clinical trial (TKT025; N = 12), its ongoing extension (TKT025EXT) and three phase III trials (total N = 82), showed that velaglucerase alfa is generally well tolerated in adult and pediatric patients. Many disease-related parameters improved significantly in two phase III trials in treatment-naive patients, and were successfully maintained in imiglucerase-experienced patients in a phase II/III switch study. Ten adults in TKT025EXT sustained improvements through 5 years, including bone mineral density. Comparison with imiglucerase shows that velaglucerase alfa is an effective, generally well-tolerated alternative enzyme replacement therapy. In vitro data suggest velaglucerase alfa may be internalized into cells more efficiently and have a lower rate of seroconversion. However, these results do not necessarily correlate with clinical efficacy.
机译:1型高雪氏病(GD)是由遗传的β-葡萄糖脑苷脂酶基因突变导致的,导致贫血,血小板减少,脾肿大,肝肿大和骨骼疾病。 Velaglucerase alfa是一种在人细胞系中通过基因激活产生的β-葡萄糖脑苷脂酶,适用于1型GD。 I / II期临床试验(TKT025; N = 12),正在进行的扩展试验(TKT025EXT)和三期III期试验(总N = 82)表明,成人和儿童患者对维拉苷酶α的耐受性普遍良好。在未经治疗的两名患者的两项III期临床试验中,许多与疾病相关的参数均得到了显着改善,并且在经历过伊米苷酶治疗的患者中,II / III期转换研究成功地维持了这些疾病参数。 TKT025EXT的10位成年人在5年中持续改善,包括骨矿物质密度。与伊米苷酶的比较表明,维拉苷酶α是一种有效的,一般耐受性良好的替代酶替代疗法。体外数据表明,维拉苷酶α可以更有效地内化到细胞中,并具有较低的血清转化率。但是,这些结果不一定与临床疗效相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号